MYLK-AS1

Across TCGA pan-cancer cohorts, MYLK-AS1 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MYLK-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MYLK-AS1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYLK-AS1 expression acts as an unfavorable survival marker, although some lineages such as UVM and UCS show a favorable association.

LIHC, UVM, and MESO are the cancer types where MYLK-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.605	0.764	<.001	113	view →
UVM	OS	Tertile	All	0.809	0.337	<.001	94	view →
MESO	DFS	Median	All	0.267	0.457	<.001	75	view →
KICH	OS	Quartile	All	0.645	1.000	.005	61	view →
UCS	OS	Median	All	0.709	0.429	.003	52	view →
READ	OS	Median	III,IV	0.630	0.278	.007	44	view →
KIRC	DFS	Tertile	II,III,IV	0.428	0.602	.007	20	view →
BLCA	OS	Quartile	IV	0.253	0.844	<.001	17	view →
LGG	OS	Tertile	All	0.936	0.820	.002	16	view →
PRAD	DFS	Median	All	0.900	0.961	.003	16	view →
THYM	OS	Tertile	II,III,IV	1.000	0.853	.013	15	view →
ACC	OS	Tertile	III,IV	0.351	0.878	.010	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MYLK-AS1–LIHC (OS)

Open the LIHC breakdown →